Everlywell Appoints Charles Cuzzell as Chief Commercial Officer and Mike Considine as Chief Product Officer to Accelerate Enterprise Expansion

Now working with four of the five largest U.S. health plans, the company's enterprise division is positioned for significant growth

AUSTIN, Texas--(BUSINESS WIRE)--Everlywell, the diagnostics and virtual care platform powering preventive and chronic care for the nation’s largest health plans, today announced continued investment in its enterprise business with the additions of Charles Cuzzell as Chief Commercial Officer and Mike Considine as Chief Product Officer. The company, best known for putting diagnostic testing in consumers' hands, has now become a trusted partner in providing both remote diagnostics and virtual care for health plans covering 170 million Americans.

Over the past decade, Everlywell has harnessed advanced diagnostics to deliver nearly one billion personalized health insights, transforming care for 60 million people and powering hundreds of enterprise partners. The company is now scaling its wrap-around care model, which includes member engagement, at-home lab testing, and NCQA-accredited virtual care.

"Health plans don't buy point solutions anymore; they buy partners who are accountable for the full care pathway and can reliably help them engage members, improve outcomes, and drive quality metrics," said Julia Cheek, Founder and CEO of Everlywell. "We've spent a decade building the at-home lab testing and virtual care infrastructure that make us a key partner to the largest payers. Charles and Mike are here to scale the enterprise commercial organization and deliver AI-driven data and care solutions that payers and health systems actually deploy."

The Preventive Care Opportunity for Health Plans

Only a fraction of adults complete the preventive services recommended for them, and the gap holds across every population a plan manages. Federal data show that just 7.2% of adults aged 35 and older receive all high-priority preventive services, a problem reflected in medical costs and quality scores alike. Everlywell's enterprise growth is concentrated in cardiometabolic health and cancer screening, the categories where plans carry some of the highest medical costs and the heaviest quality-score weighting. The platform supports more than 25 HEDIS measures, including:

• GSD (Glycemic Status Assessment for Patients with Diabetes)
• KED (Kidney Health Evaluation for Patients with Diabetes)
• CBP (Controlling High Blood Pressure)
• COF-E (Follow-Up After Positive Colorectal Cancer Non-Invasive Screening Test)
• CCS-E (Cervical Cancer Screening)

Last year, the company introduced Eva, an AI-powered platform that translates complex biomarker data into clear, personalized health insights and helps health plans engage members with timely outreach, coordinated care pathways, and actionable next steps. Most recently, Everlywell partnered with Waters Corporation to offer the Onclarity™ HPV Self-Collection Kit, tested with the BD Onclarity™ HPV Assay, the most comprehensive FDA-cleared at-home HPV cervical cancer screening tool available in the U.S. today.¹ The diagnostic-led solution helps health plans expand access to cervical cancer screening and makes it easier for eligible members to complete recommended preventive care.

Expanding Everlywell’s Leadership Team

Charles Cuzzell, Chief Commercial Officer

As Chief Commercial Officer, Cuzzell owns Everlywell's enterprise organization end-to-end, including sales, partnerships, account management, and customer success.

“I’m excited to join Everlywell and build on the important work already underway to help health plans engage members, close care gaps, and make high-quality preventive care easier to access,” said Charles Cuzzell, Chief Commercial Officer of Everlywell. “Everlywell’s platform brings together diagnostics, digital engagement, and connected care to help payers and employers reach members with timely, actionable health insights and clear next steps. I look forward to building a commercial organization ready to meet that need at scale.”

Mike Considine, Chief Product Officer

As Chief Product Officer, Considine leads product and design across the company.

“Throughout my career, I’ve focused on building products that turn complex healthcare data into clearer decisions and better action,” said Mike Considine, Chief Product Officer of Everlywell. “Everlywell is uniquely positioned to connect advanced diagnostics with a digital experience that helps individuals understand what their results mean and what to do next. I’m excited to advance a product strategy that makes that experience simpler, more personalized, and easier for health plans to deliver at scale.”

To learn more about Everlywell and the company’s enterprise solutions, visit https://www.everlywell.com/enterprise

About Everlywell

Everlywell is a digital health company transforming complex biomarker data into life-changing insights, seamlessly integrating advanced diagnostics, virtual care, and patient engagement to expand access, close care gaps, and improve health outcomes across the full care journey. Through at-home and clinician-supported lab testing and virtual care experiences, Everlywell empowers individuals with the information they need to make more informed health decisions.

Over the past decade, Everlywell has delivered nearly one billion personalized health insights, transformed care for 60 million people, and powered hundreds of enterprise partners, including four of the top five largest health plans in the U.S. that cover 170 million insured lives. In 2025 alone, an estimated one in 94 U.S. households received an Everlywell test, solidifying its spot as the #1 at-home testing brand in the country. Fueled by AI and built for scale, Everlywell is breaking down barriers, closing care gaps, and unlocking a more connected healthcare experience that is smarter, faster, and more personalized. Learn more at everlywell.com.

¹There are currently two FDA-approved HPV tests with extended genotyping with different configurations. The BD Onclarity™ HPV Assay individually identifies 6 high-risk HPV genotypes and strategically groups 3 results for 8 moderate risk HPV genotypes.